In the original publication of "Converting oral to longacting injectable antipsychotics: a guide for the perplexed," some errors appeared in Tables 1 and 2 and on pages 23-24. The corrections made to rectify these errors are noted below, and the article has been corrected online. Table 1 , second column: the headers "Aripiprazole" and "Dehydroaripiprazole" were shifted to the right; the number "33333333" was deleted Table 2 , fourth column: "84-95 days (deltoid)" was replaced with "30-33"; "118-139 days (gluteal)" was deleted Table 2 , fifth column: "30-33" was replaced with "84-95 days (deltoid)"; "118-139 days (gluteal)" was added Page 23: "Naturalistic data from a cohort of 217 German patients treated with oral paliperidone ER show a dose correlation of 4.7 (±2.9) ng/ml for every milligram of oral paliperidone" was replaced with "Naturalistic data from 217 patients treated with oral paliperidone ER show a dose correlation of 4.7 (±2.9) ng/ml per milligram." Page 23: "Using this formula, a mean plasma level of 28.4 ng/ml seen with 234mg of paliperidone palmitate after 12 weeks appears comparable to approximately 6 mg/d of oral paliperidone" was changed to "However, this provides dosing guidance 2-fold higher than PK models of larger samples. The package insert thus recommends that paliperidone palmitate 117 month equals 6 mg of oral paliperidone." Page 24: "however, the half-life is markedly longer than other LAI preparations and this property not only permits" was changed to "however, the long half-life of 53.9-57.2 days not only permits"
The author and publisher apologize for these errors.
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